Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer.

ACS chemical biology - 16 Apr 2021

Wang Xianwu, Luo Xi, Tian Yunpeng, Wu Ting, Weng Jian, Li Zhu, Ye Feng, Huang Xuefei

Abstract excerpt

While Cetuximab can be used to treat KRAS wild-type colon cancer cells by targeting EGFR and inhibiting the activation of downstream signaling pathways, it exhibits little therapeutic effect on KRAS mutant colon cancer cells. Natural killer (NK) cells are a class of powerful immune cells with anticancer activities. However, NK cells typically lack inherent tumor targeting abilities. Here, a new method is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Genes, ras

Share to Killer Cells, Natural

Share to Mutation

Source

Identifiers

PMID: 33829754
DOI: 10.1021/acschembio.1c00022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer.PMID 33829754Read ↗

Protein-Targeted Glycan Editing on Living Cells Disrupts KRAS Signaling.Semantic proximity Read ↗

Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.Semantic proximity Read ↗

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organismSemantic proximity Read ↗

An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in CancerSemantic proximity Read ↗

Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cellsSemantic proximity Read ↗

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutationSemantic proximity Read ↗

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signalingSemantic proximity Read ↗

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.Semantic proximity Read ↗

TRAIL ‐conjugated liposomes that bind natural killer cells to induce colorectal cancer cell apoptosisSemantic proximity Read ↗

Efficient Preparation and Bioactivity Evaluation of Glycan-Defined Glycoproteins.Semantic proximity Read ↗

Antibody Conjugates with Unnatural Amino AcidsSemantic proximity Read ↗

Amber Codon Mutational Scanning and Bioorthogonal PEGylation for Epitope Mapping of Antibody Binding Sites on Human Arginase-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.